Director/PDMR Shareholding

Acquisition of shares by CEO                          

Oxford, UK, 18 October 2005 The Board of Physiomics plc (AIM:PYC), a European
systems biology simulation company, was informed on 17 October that Dr John
Savin, CEO, has paid, with the agreement of the Board, in cash for 54,688
shares at 2p per share. These shares were issued in December 2004 in respect of
a small overcharge of third party flotation costs.

Dr Savin's shareholding has increased to 604,688 ordinary shares of 0.04p
comprising 0.26% of the Company's issued share capital.

                                    --ENDS-                                    

For further information please contact:

 

Physiomics plc

Mr David Evans (Chairman) Tel: [phone]

Dr John Savin (CEO) Tel: [phone]

 

Northbank Communications Tel: [phone]

Emma Palmer (financial enquiries)

Fiona Brown/Rowan Minnion (media enquiries)


Notes to Editors

Physiomics plc

Physiomics plc (AIM:PYC) is a systems biology company applying computer-based
simulations of cell behaviour in drug development, aimed at reducing the high
cost and attrition rates of clinical trials. As 80-90 per cent of all clinical
drug candidates fail to reach the market, estimates show even a ten per cent.
overall improvement in success rates could reduce the cost of one drug's
development by up to $242 million, from the current estimate of around $800
million.

Physiomics is currently focused on optimising the design of cancer clinical
trials as a service to major pharmaceutical companies. In addition, it has
secured an option to in-license two innovative molecules in the cancer area
from Cronos therapeutics.Physiomics has a major collaboration with Bayer
Technology Services GmbH to develop globally clinical response prediction
services using both companies' proprietary technologies and mathematical cell
models, including the SystemCell® technology developed by Physiomics. In June
2005, Physiomics became is a distributor of Bayer's PK-Sim® product for
understanding the way pharmaceuticals are distributed round the body.
Physiomics, based in Oxford, UK, was founded in 2001, and floated on AIM in
2004.

For further information, please visit www.physiomics-plc.com

SystemCell is a registered trademark of Physiomics plc